Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor

Eitemau Tebyg

• Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors
  gan: Niwakawa, Masashi, et al.
  Cyhoeddwyd: (2013)
• Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
  gan: Steeghs, Neeltje, et al.
  Cyhoeddwyd: (2009)
• Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
  gan: Rodenburg, RJ, et al.
  Cyhoeddwyd: (2019)
• Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
  gan: Bhargava, Pankaj, et al.
  Cyhoeddwyd: (2011)
• The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species specific insoluble metabolite formation
  gan: Lolkema, Martijn P., et al.
  Cyhoeddwyd: (2015)